FDA approves Amneal Pharmaceuticals’ Tramadol/APAP tablets

Amneal Pharmaceuticals is pleased to announce that it received U.S. FDA approval to manufacture combination Tramadol HCl in 37.5 mg strength and Acetaminophen in 325 mg strength (Tramadol/APAP) in tablet form effective December 9, 2009. Amneal’s generic is an AB-rated, therapeutically equivalent alternative to Ultracet® (a licensed trademark of Ortho-McNeil Janssen). U.S. sales of Tramadol/APAP were $61 MM according to June 2009 IMS Health market data.

Related posts:

1. FDA approves manufacture of Amneal Pharmaceuticals’ Nizatidine Oral Solution
2. FDA approves Mylan Pharmaceuticals’ ANDA for Levetiracetam Tablets
3. Sales revenue from Labopharm’s once-daily tramadol increases to $4.7M for fourth-quarter fiscal 2009